Fair Price Working Group - September, 1998

Please consider having your organization sign onto the attached Consensus Statement. It concerns the eventual price of two new potent drugs: the nucleoside analog abacavir (Ziagen®) and the nNRTI efavirenz (Sustiva®). Both of these compounds are under FDA review and no doubt will soon enter the market. There has been considerable speculation that either or both will be priced far higher than other nukes and nNRTIs, perhaps even in the range of the protease inhibitors that they would supplement or sometimes replace. Such a move would substantially increase the cost of health care for a great number of people with HIV. The ability of public programs such as ADAP and Medicaid to support HIV treatment would be further limited, and even private HMOs may object to prescribing these new drugs. We need to send a loud, clear and united message immediately before final pricing decisions are made by the sponsors, Dupont Pharma and Glaxo Wellcome.

We hope that this statement becomes the first step in a wider campaign over the cost of HIV treatments to be directed at all sponsors. Some companies in the past year have quietly raised prices on drugs that already bore high price tags, without strong protest from the HIV-affected community. There is no justification for these increases other than "what the market will bear." But as combination regimens become ever more elaborate, people with HIV as well as their third-party payers will likely face medical costs over the course of a lifetime rising into the stratosphere. The pharmaceutical industry, meanwhile, stands to reap a windfall. Companies have less justification for squeezing high short-term profits from their drugs since people will be using them for longer periods of time. Make no mistake about it -- each unfair pricing action cuts off the lifeline of treatment for another portion of the population!

Please join with us in putting this urgent issue on the front burner of AIDS activism and support our efforts by asking your agency or organization to sign-on to the attached consensus statement now. Also, please watch for further communiqués on this important issue.

Time is of the essence! To endorse the attached consensus statement, please reply ASAP to::

FAIR PRICE WORKING GROUP

Consensus Statement on the Pricing of Abacavir and Efavirenz

We, the undersigned, have grave concerns regarding the overall cost of therapy for HIV disease. While we are heartened by the progress made in moving toward simpler, easier to use regimens, we are dismayed by the possibility that prices of new drugs in the nucleoside and non-nucleoside RT inhibitor class might be similar to those of protease inhibitors, rather than other drugs in their own respective classes. Such inappropriate pricing will quickly outweigh any possible added benefits of new drugs like (Ziagen®) and efavirenz (Sustiva®). As drugs become available which might facilitate better adherence and possibly more durable long-term treatment, manufacturers should be planning to lower the daily cost of their regimens, not increase them. The long-term survival afforded by the present generation of therapies makes it possible for manufacturers to set lower, or at lest stable prices, and still have adequate incentive to reinvest in continued development of HIV/AIDS drugs. Recently cited reductions in the overall cost of health care for HIV infected people will almost certainly be reversed in coming years if manufacturers continue to increase or maintain current pricing levels. We are in a new era in the treatment of HIV disease and rethinking drug pricing which reflects this changing reality is long overdue.

To the best of our knowledge, the development costs of these drugs were not comparable to those of the first protease inhibitors, nor is on-going cost of product as high. Quite the contrary, because of the efficiency of the new drugs, far fewer pills and thus much less physical product is required for dosing on a daily basis. Similarly, there has been nothing extraordinary about the cost of clinical trials required to bring these drugs to market.

Abacavir and efavirenz are likely to be used by both treatment naive and treatment experienced patient populations, making their potential market very large. If the prices are high and either or both drugs used in naive populations in place of existing drugs, the overall cost of therapy will go up. An even greater cost penalty will occur for treatment experienced patients, who are likely to use both drugs together, often in combination with a protease inhibitor. This would lead to an unacceptably high cost of therapy. We cannot stand idly by while the price of living with HIV disease escalates so rapidly.

State ADAP programs have limited amounts of money allocated to them each year. Many of the state's annualized programs are bankrupt prior to fiscal year-end. Some state ADAP and Medicaid programs have removed vital medications to prevent and treat opportunistic infections from their formularies. State ADAP and Medicaid programs are under close scrutiny by governmental panels in order to cut costs. The price of one drug can affect the availability of other medications. Increasingly, this same sad scenario is beginning to affect the availability of drugs within HMO settings. The price of these drugs will have a pervasive impact on the overall quality of care people with HIV/AIDS receive in this country.

The sponsors of abacavir and efavirenz have both expressed a strong desire to create goodwill and cooperative working relationships with the community. No one wants to see those relationships jeopardized or eroded over this issue, but that surely will happen if pricing is inappropriate. As we face another round of price setting, industry must recognize this is an issue that is now moving to the forefront. Exploitative pricing will trigger widespread hostility, contentious debate and closer scrutiny of industry practices in general. This will have far reaching consequences. Have DuPont Pharma and Glaxo Wellcome considered the possible repercussions of opening this Pandora's box? Are you willing to risk the aftermath of ill will within the community and to be held accountable within industry?

Therefore, we must clearly state for the record that the only acceptable prices for these drugs must be in accordance with other drugs of their respective classes. We urge manufacturers to immediately begin a dialogue with the community about this pricing issue and not presume it can simply announce a price immediately prior to regulatory approval, without consequences, as a fait accompli.

____________________________________
Signature

____________________________________
Name of Organization (print legibly)

ORGANIZATIONAL ENDORSEMENTS as of 10/04/98

1. ABRACO/ASSOCIACAO DE APOIO A PESSOIAS COM VIH/SIDA, LISBON, PORTUGAL
2. ACT UP BOSTON, BOSTON, MA
3. ACT UP GOLDEN GATE, CA
4. ACT UP EAST BAY, CA
5. ACT UP PHILADELPHIA, PHILADELPHIA, PA
6. ACT UP NEW YORK, NY*
7. ACTIONS TRAITEMENTS, PARIS, FRANCE
8. AIDS ADVOCACY ALLIANCE, HONG KONG, CHINA
9. AIDS ACTION, WASHINGTON, D.C.
10. AIDS ALLIANCE OF MARTHA'S VINEYARD, MASSACHUSETTS
11. AIDS CARE, INC., VENTURA, CA
12. AIDS COALITION OF CHATAUQUA COUNTY, NY
13. AIDS COMMUNITY NETWORK
14. AEGIS/AIDS EDUCATION GLOBAL INFORMATION SYSTEM, CA
15. AFRICA CONSULTANTS INTERNATIONAL/ACI, DAKAR, SENEGAL
16. AIDS LAW PROJECT OF PENNSYLVANIA, PHILADELPHIA, PA
17. AIDS, MEDICINE & MIRACLES, BOULDER, CO
18. AIDS NETWORK, WEST VIRGINIA
19. APLA/AIDS PROJECT LOS ANGELES, CA
20. ASIAN SOLIDARITY AGAINST AIDS, INDIA
21. AIDS RESEARCH ALLIANCE, LOS ANGELES, CA
22. AIDS SERVICES OF DALLAS, TX
23. AIDS TREATMENT CENTRE, PRETORIA, SOUTH AFRICA
24. AIDS TREATMENT INITIATIVES, ATLANTA, GA
25. AIDS TREATMENT NEWS, CA
26. AIDS TREATMENT DATA NETWORK, NY
27. AIDS WASTING FOUNDATION
28. AMERICAN SOCIAL HEALTH ASSOCIATION, RESEARCH TRIANGLE PARK, NC
29. ANDREW ZIEGLER FOUNDATION
30. ASIAN & PACIFIC ISLANDER WELLNESS CENTER: COMMUNITY HIV/AIDS SERVICES, SAN FRANCISCO, CA
31. AUSTRALIAN FEDERATION OF AIDS, TREATMENT OFFICERS NETWORK, which represent all States and Territories of Australia
32. BEING ALIVE: PEOPLE WITH HIV/AIDS ACTION COALITION OF LOS ANGELES, CA
33. BELLE REVE, NEW ORLEANS, LA
34. BLUE RIDGE PWA EMPOWERMENT PROJECT, ASHEVILLE, NC
35. BODY POSITIVE NORTH WEST, UNITED KINGDOM
36. BRAZILIAN INTERDISIPLINARY AIDS ASSOCIATION/ABIA, BRAZIL
37. CANADIAN TREATMENT ADVOCATES COUNCIL, TORONTO, ONTARIO, CANADA
38. CARETEAM, MYRTLE BEACH, SC
39. CENTER FOR AIDS RESEARCH, NY
40. CENTRAL IDAHO HIV/AIDS CLINIC, BOISE, ID
41. CHARLOTTE HIV/AIDS NETWORK, INC.
42. CHC/THE CORRECTIONAL HIV CONSORTIUM
43. CHICAGO ADULT ACTG CAB/COMMUNITY ADVISORY BOARD, CHICAGO, IL
44. COASTAL AIDS NETWORK, BELFAST, ME
45. COCD-SIDA, QUEBEC, CANADA
46. COMMUNITY ADVISORY BOARD, AACTG, HAWAII
47. COMMUNITY OUTREACH INTERVENTION PROJECTS, CHICAGO, IL
48. COMMUNITY PRESCRIPTION SERVICE, INC., NY
49. COMMUNITY PROGRAMS FOR CLINICAL RESEARCH ON AIDS STATISTICAL CENTER, COORDINATING CENTER FOR BIOMETRIC RESEARCH, DIVISION OF BIOSTATISTICS, SCHOOL OF PUBLIC HEALTH, UNIV. OF MINNESOTA, MINNEAPOLIS, MN
50. COORDINADORA NACIONAL DE PERSONAS VIVIENDO CON VIH/SIDA, CHILE (National Coordinating Committee of People Living with HIV/AIDS, Chile)
51. CORPORACION CHILENA DE PREVENCION DEL SIDA, SANTIAGO, CHILE
52. CPCRA CAB, SAN FRANCISCO, CA
53. CRITICAL PATH AIDS PROJECT, PHILADELPHIA, PA
54. FAIR/FOUNDATION FOR AIDS & IMMUNE RESEARCH, CA
55. FAMILY AIDS CARING TRUST, ZIMBABWE
56. FAMILY PRACTICE MEDICAL CENTER, BOISE, ID
57. FASE/FUNDACION ANTI-SIDA ESPANA (SPANISH FIGHTING AIDS FOUNDATION) MADRID, SPAIN
58. FUNDACION R.E.D.- RECURSOS-ESTUDIOS DESARROLLOS, ARGENTINA
59. GLOBAL NETWORK OF PEOPLE LIVING WITH HIV/AIDS (GNP+) AMSTERDAM, THE NETHERLANDS
60. GMHC/GAY MENS HEALTH CRISIS, NY
61. GTT/GRUPO DE TRABAJO SOBRE TRATAMIENTOS DEL VIH, BARCELONA, SPAIN
62. HARVARD/BOSTON MEDICAL CENTER AIDS CLINICAL TRIALS UNIT, ACTG COMMUNITY ADVISORY BOARD
63. HBHC AIM PROJECT, CHICAGO, IL
64. HIVCARE & CLINICAL RESEARCH, SAINT FRANCIS MEMORIAL HOSPITAL, S.F., CA
65. HIV CASE MANAGEMENT PARTNERSHIP PROJECT, PORTLAND, OR
66. HIV NACHRICHTEN, GERMANY
67. HOLISTIC HEALTH CENTER
68. HOPE FOR THE PEE DEE
69. HYACINTH AIDS FOUNDATION OF NEW JERSEY, NJ
70. IAPAC/INTERNATIONAL ASSOCIATION OF PHYSICIANS IN AIDS CARE, CHICAGO, IL
71. IHO/INDIA HEALTH ORGANISATION, BOMBAY, INDIA
72. JOINT RESEARCH SERVICES, NAIROBI, KENYA
73. LACCASO/LATIN AMERICAN COUNCIL OF AIDS SERVICE ORGANIZATIONS, BUENOS AIRES, ARGENTINA
74. LETRA S SALUD, SEXUALIDAD Y SIDA, MEXICO
75. LIFEFORCE, VANCOUVER, WA
76. LIGHTHOUSE GROUP, ASHEVILLE, NC
77. LILA NAZIONALE (25 Branches operating throughout Italy) MILAN, ITALY
78. LOWELL COMMUNITY HEALTH CENTER, LOWELL, MA
79. MAHA, MIGRANTS CONTRE LE SIDA, BAGNOLET, FRANCE & GENEVA, SWITZERLAND
80. MID-FAIRFIELD AIDS PROJECT, WESTPORT, CT
81. NAM PUBLICATIONS, UNITED KINGDOM
82. NATAP/NATIONAL AIDS TREATMENT ADVOCACY PROJECT, NY
83. NMAC/NATIONAL MINORITY AIDS COUNCIL, WA
84. NEW ORLEANS CENTER FOR LIVING, NEW ORLEANS, LA
85. NEW YORK PEER AIDS EDUCATION COALITION
86. OLYMPIC COMMUNITY HEALTH ASSOCIATES, PORT ANGELES, WA
87. PECOS VALLEY HIV/AIDS RESOURCE CENTER, ROSWELL, NM
88. PEDIATRIC CCU OF THE PACTG
89. PINK PAPER, THE
90. PLWHA/PEOPLE LIVING WITH HIV/AIDS, VICTORIA, AUSTRALIA
91. PHOENIX BODY POSITIVE, PHOENIX, AZ
92. POZ MAGAZINE, NEW YORK, NY
93. PROJECT INFORM, SAN FRANCISCO, CA
94. PROVINCETOWN POSITIVE PEOPLE WITH AIDS COALITION, MA
95. PWA HEALTH GROUP, NY
96. PWA-RAG/PRISONERS WITH AIDS-RIGHTS ADVOCACY GROUPS, INC.
97. RESEARCH SANCTUARY, CA
98. REGIONAL ACTG COMMUNITY ADVISORY BOARD, CHICAGO, ILLINOIS
99. RELARD/LA RED LATINO AMERICANA DE REDUCION DE DANOS/LATIN AMERICAN HARM REDUCTION NETWORK, BUENOS AIRES, ARGENTINA
100. RIVER FUND AIDS FOUNDATION, THE, SEBASTIAN, FL
101. RYAN WHITE CENTER, LITTLE ROCK, ARKANSAS
102. RYAN WHITE PLANNING COUNCIL, WASHINGTON, DC
103. RYAN WHITE TITLE II CONSORTIUM, SOUTHWEST WASHINGTON, WA
104. SAN FRANCISCO AIDS FOUNDATION, SAN FRANCISCO, CA
105. SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH, SAN FRANCISCO, CA
106. SAN JOAQUIN AIDS FOUNDATION, THE STAFF OF, STOCKTON, CA
107. SEARCH FOR A CURE, BOSTON, MA
108. SISTERS OF ST. ELIZABETH OF HUNGARY, CA
109. STEP/SEATTLE TREATMENT EDUCATION PROJECT, SEATTLE, WA
110. SWAA INTERNATIONAL, DAKAR, SENEGAL
111. SWAA/SOCIETY FOR WOMEN IN AIDS IN AFRICA
112. SOUTHERN TIER AIDS PROGRAM, NY
113. ST. PETERS HOUSE PROJECT, SURREY, UNITED KINGDOM
114. TAG/TREATMENT ACTION GROUP, NY
115. TERTULIA, GUATEMALA CITY, GUATEMALA
116. TEXAS AIDS NETWORK, TX
117. TITLE I MINNESOTA HIV SERVICES PLANNING, MINNEAPOLIS, MN
118. TITLE II COMMUNITY AIDS NATIONAL NETWORK, WASHINGTON, DC
119. UNION POSITIVA, INC., MIAMI, FL
120. UNISON MEDICARE & RESEARCH CENTRE, BOMBAY, INDIA
121. UNITED FOUNDATION FOR AIDS, MIAMI, FL
122. UNITED SERVICES FOR AIDS FOUNDATION, NEW ORLEANS, LA
123. UNIV. OF CALIFORNIA, SAN DIEGO ACTU CAB/COMMUNITY ADVISORY BOARD, CA
124. UNIV. OF CENTRAL FLORIDA, HIV-AIDS EDUCATION OFFICE, ORLANDO, FL
125. UNIV. OF PUERTO RICO, SCHOOL OF MEDICINE, ADULTS ACTU-SITE 5401, SAN JUAN, PUERTO RICO
126. UNIVERSITY OF SUSSEX, INSTITUTE OF DEVELOPMENT STUDIES-PARTICIPATION GROUP , BRIGHTON, ENGLAND
127. "U"CAN/UPPER CAPE AIDS NETWORK, WAQUOIT, MA
128. VICTORIAN AIDS COUNCIL, MELBOURNE, AUSTRALIA
129. WE THE PEOPLE, PHILADEPHIA, PA
130. WELLNESS CENTER OF SOUTH FLORIDA, FL
131. WESTERN NORTH CAROLINA HIV/AIDS CONSORTIUM, ASHEVILLE, NC
132. WNC POSITIVE LIVING NEWS, NC
133. WOMEN ALIVE COALITION, LOS ANGELES, CA, OAKLAND, CA

1. Moises Agosto, Dir.Treatment Advocacy, NMAC/National Minority AIDS Council, Washington DC
2. Michael Ahern, San Francisco, CA
3. Ernie Alexander, PLWA, Roswell, New Mexico
4. Hector Anabitarte, Secretary General, FASE/Fundaction Anti-SIDA Espana (Spanish Fighting AIDS Foundation), Madrid, SPAIN
5. Laura E. Asturias, Editor, Tertulia, Guatemala City, GUATEMALA
6. Joan Atkinson, Johns Hopkins University, MD
7. Bill Bahlman, Founding Member, ACT UP New York, New York, NY
8. Mark W. Baker, Provincetown Positive/PWA Coalition, Provincetown, MA
9. Ron Baker, Ph.D., Director of Treatment Advocacy, San Francisco AIDS Foundation, CA
10. Elisabeth Benga-De, M.D., SWAA International, Program Officer, Dakar. SENEGAL
11. Dr. Ezio Baraldi, AIDS Treatment Centre, Pretoria, SOUTH AFRICA
12. Irl Barefield, Director, HIVCare & Clinical Research, Saint Francis Memorial Hospital, SF, CA
13. Stephen J. Barksby, Body Positive North West, UNITED KINGDOM
14. Joel Beard, aidsinfonyc.org, NY
15. Jorge Beloqui, GIV, Sao Paulo, BRAZIL
16. Jeanne Bergman, Ph.D., New York Peer AIDS Education Coalition, NY
17. Mabel Bianco, Regional Secretary, LACCASO/Latin American Council of AIDS Service Organizations, Buenos Aires, ARGENTINA
18. Louise Binder, Co-Chair, Canadian Treatment Advocates Council, CTAC, Toronto, ONT, CANADA
19. B. Blevins, Wilmington, NC
20. Jeff Bloom, Title II Community AIDS National Network, Washington, DC
21. Carlos Bonfil, Letra S Salud, Sexualidad, Sida, MEXICO
22. Marie-Hélène Bourcier, Researcher, Lesbians & AIDS, Paris, FRANCE
23. Mark Bowers, Education Director, Andrew Ziegler Foundation & Education & Outreach, St. Francis Hospital, San Francisco, CA
24. Alejandro Brito, Letra S Salud, Sexualidad, Sida, MEXICO
25. Diane Brown, Southern Tier AIDS Program, NY
26. Gregory S. Britt, CEO, AIDS Research Alliance, Los Angeles, CA
27. Sally Brookins, Colorado Springs, CO
28. Nicholas Brookins, Colorado Springs, CO
29. Robert J. Brunet PLWA, Knoxville TN
30. Michael BuitrĒn, Center for Behavioral Research & Services
31. Mario Burgos, Fundacion R.E.D./Recursos-Estudios Desarrallos, ARGENTINA
32. Carola Burroughs, AIDS Wasting Foundation
33. Paul Buzzell, San Francisco, CA
34. Jill Cadman, Associate Editor, GMHC's Treatment Issues, New York, NY
35. Amaria Jose Campos, ABRACO/Associacao de Apoio a Pessoas Com VIH, Lisbon, PORTUGAL
36. Joe Carpenter, The Pink Paper
37. Daniel Conditt, HIV Case Manager , Long Beach, CA
38. Rob Capone, Exec. Director, We The People, Philadelphia, PA
39. George M. Carter, Director, Treatment Information Development, DAAIR, NY
40. Ross Carter-Jaye, Director, St. Peters House Project, Surrey, United Kingdom
41. Thomas E. Casey, Atlanta GA
42. Ben Cheng, Project Inform, San Francisco, CA
43. Rolf Christensen, D.D.S., University of Washington, Seattle, WA
44. Pablo Colon, Director Treatment Education & Advocacy, GMHC, New York, NY
45. Brian Coppedge, STEP/Seattle Treatment Education Project, Seattle, WA
46. Andrea Cornwall, University of Sussex, IDS/Institute of Development Studies -Participation Group, Brighton, ENGLAND
47. Jim Corti, Research Sanctuary, Los Angeles, CA
48. Myron C. Crider, Morrow, Georgia, USA
49. Robert Dal Porto, President, Board of Directors, Being Alive: People with HIV/AIDS Action Coalition, Los Angeles, CA
50. Julie Davids, Director of Education , Project TEACH & Philadelphia FIGHT, Philadelphia, PA
51. Paul Davis, ACT UP Philadelphia, PA
52. John Daye, PLWHA/People Living with HIV/AIDS, Victoria, AUSTRALIA
53. Carolyn DeAngelis, PLWA, Volunteer Speaker, East Brunswick, NJ
54. Larry Dearman, Case Manager, Ryan White Center, Little Rock, AK
55. Martin Delaney, Founding Director, Project Inform, CA
56. Joseph D. DeMaria, Ocean, NJ
57. Daniel J. DeNoon, Senior Editor, AIDS Weekly Plus
58. Arturo Diaz, Letra S Salud, Sexualidad, Sida, MEXICO
59. Michael Donnelly, ACT UP Golden Gate, San Francisco, CA
60. Steven Dornbusch, Los Angeles, CA
61. Sharon E. Douglass, M.S., Associate Professor/Director, HIV-AIDS Education Office, Univ. of Central Florida, Orlando, FL
62. Linda Downie, Chair, Ryan White Title II Consortium, SW Washington, WA
63. Robert L. Drake, Cleveland, OH
64. Earl Driscoll, ACT UP Philadelphia, PA
65. Jerry A. Edwards, MPH, Immediate Past President & Board Member, Western NC HIV/AIDS Consortium, Inc., Asheville, NC
66. Kathy Edwards, Co-Chair, CAB-AACTG-Hawaii
67. Ferd Eggan, AIDS Coordinator, City of Los Angeles, CA
68. Roberta Eidman,Triple Hayz Corporation, Los Angeles, CA
69. Sister Mary Elizabeth, AIDS Education Global Information System (AEGIS), CA
70. Gary Engelberg, Director, Africa Consultants International/ACI, Dakar, SENEGAL
71. Georgia Fallas, R.N., HCA-Special Diseases, Orange County, CA
72. Brian Feit, Chair, Pediatric CCU of the PACTG, PA
73. Ferrari, MAHA, Geneva, SWITZERLAND
74. Nan Feyler, Esq. Executive Director, AIDS Law Project of Pennsylvania, Philadelphia, PA
75. Colatta Porter-Field, Myrtle Beach, SC
76. Manuel Figueroa, Letra S Salud, Sexualidad, Sida, MEXICO
77. Anna Forbes, MSS, AIDS and Women's Health Policy Consultant, Philadelphia, PA
78. Daniel Forest
79. Geoff Foster, M.D., Director, Family AIDS Caring Trust, ZIMBABWE
80. Tim Frasca, Corporacion Chilena de Prevencion del Sida, Santiago, CHILE
81. Vernella French, United Services for AIDS Foundation, New Orleans LA
82. Ruben Gamundi, Treatment Coordinator, APLA/AIDS Project, Los Angeles, CA
83. Debbie Garlock, PLWA, AIP/AIDS Intervention Project, Altoona PA & FAAN/Franklin Area AIDS Network, Chambersburg, PA
84. Gregory J. Garlock, AIP/AIDS Intervention Project, Altoona, PA & FAAN/Franklin Area AIDS Network, Chambersburg , PA
85. Alfred L. Gaspar
86. Jacques Gelman, President, COCD-SIDA, Quebec, CANADA
87. Stephen Gendin, President, Community Prescription Svcs., Exec. VP., POZ, New York, NY
88. Jeff Getty, ACT UP Golden Gate, San Francisco, CA
89. Ian C. Gibson-Smith, AIDS Network, West Virginia
90. I.S.Gilada, M.D., Secretary General, Indian Health Organisation & UNISON Medicare & Research Centre; Bombay, INDIA
91. Dave Gilden, Editor, GMHC's Treatment Issues, New York, NY
92. Susan Goggans, Director Client Svcs., Ryan White Center, Little Rock, AK
93. Steve Goodson, "a concerned care provider", Raleigh, NC
94. Robert Goslin, Resource Education Coord., The New Orleans Center for Living, New Orleans, LA
95. William Greene, Board Member & Community Advocate, AIDS Care, Inc., Ventura, CA
96. Linda Grinberg, Pres.,FAIR/Foundation for AIDS & Immune Research, Project Inform Board, CA
97. Jeff Gustavson, ACT UP Golden Gate, San Francisco, CA
98. David Hans-U. Haerry, Bern, SWITZERLAND
99. Michael Haggerty, MPH, Executive Director, CHC/The Correctional HIV Consortium
100. Bridget Haire, PLWHA/People Living with HIV/AIDS, Victoria, AUSTRALIA
101. Mark E. Hammann, Western North Carolina HIV/AIDS Consortium, NC
102. Julie A. Hanson, Council Staff, Title I MN HIV Services Planning Council, Minneapolis, MN
103. Lisa Harewood, Study Coordinator, Center for AIDS Research, NY
104. Agnes Harley, Philadelphia FIGHT, Project TEACH & ACT UP Philadelphia, PA
105. Rebecca Harmon, HIV Case Management Partnership Project, Portland, OR
106. Mark Harrington, Treatment Action Group, New York, NY
107. Hassan J. Gibbs, Consumer Advocate, Philadelphia FIGHT & Project TEACH, Phila.,PA
108. Leslie Hanna, Acting Editor, BETA/San Francisco AIDS Foundation, S.F., CA
109. William T. Healy, Member, Ryan White Oversight Committee, Hawaii
110. Sharon Sharon Henkel, Polio Network, St. Louis, Missouri
111. Sharon Hiers, Careteam, Inc, Myrtle Beach, NC
112. Liz Highleyman, Acting Editor, BETA/San Francisco AIDS Foundation, S.F., CA
113. Deena Hilton, Hope for the Pee Dee
114. Thomas A. Hemmingsen, Chicago Adult ACTG CAB, Chicago, IL
115. Alfredo Hernandez, Central Idaho HIV/AIDS Clinic, Boise, ID
116. Mark J. Hoffman, Treatment Advocate, Phoenix Body Positive, Phoenix, AZ
117. Tom Hofstad, San Joaquin Aids Foundation, Tracy, CA
118. Carlton Hogan, Community Programs for Clinical Research on AIDS Statistical Center, Coordinating Center for Biometric Research, Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN
119. Robert Hutnick, PLWA, East Brunswick, NJ
120. John Iverson, ACT UP East Bay, Oakland, CA
121. Jeff Jacobs, AIDS Action, Washington, DC
122. Lawrence Eli Jaffe
123. John S. James, Publisher, AIDS Treatment News, San Francisco, CA
124. Richard Jefferys, Access Project Director, AIDS Treatment Data Network, New York, NY
125. Charles Johns, UCAN/Upper Cape AIDS Network, Waquoit, MA
126. Neil Johnsen, President, Lifeforce, Vancouver, Washington
127. Cleve Jones, Founder, The Names Project AIDS Memorial Quilt, San Francisco, CA
128. Loren Jones, Clinical Trials Peer Advocate, W.O.R.L.D., Oakland, CA
129. Benson Okall Jowi, Coordinator, Joint Research Services, Nairobi, KENYA
130. Paul Akio Kawata, Executive Director, NMAC/National Minority AIDS Council, Washington, DC
131. B.Kennedy, Health Care Agency, HIV Individual Provider, FNP-C, Santa Ana, CA
132. Jeff Kimbro, Executive Director, Careteam, Inc., Myrtle Beach, SC
133. David Kiviaho, Program Director, Belle Reve, New Orleans, LA
134. Colin Kovacs, FRCP, Toronto, CANADA
135. Kiyoshi Kuromiya, Critical Path AIDS Project, Philadelphia, PA
136. Renee Lambert, Hope for The Pee Dee, Case Manager, Florence, SC
137. Lark Lands, Science Editor, POZ Magazine, New York, NY
138. Stuart Lane, Mid-Fairfield AIDS Project, Westport, CT
139. Garrett R. Lanzy, Endicott, NY
140. James Learned, PWA Health Group, New York, NY
141. Stephen LeBlanc, ACT UP Golden Gate, San Francisco, CA
142. Dominic LeDesmu, Darien, IL
143. Gina Lee, Gahanna, OH
144. Brenda Lein, Project Inform, San Francisco, CA
145. Jules Levin, National AIDS Treatment Advocacy Project, New York, NY
146. Nancy MacNeil, Women Alive Coalition, Los Angeles, CA
147. Thomas L. Magee, MD, Los Angeles, CA
148. Lana J. Roston-Mahoney, RN, BS, Olympic Community Health Associates, Port Angeles, WA
149. Naisiadet Maina, Vice President, SWAA, Society of Women and AIDS in Africa, Dakar, SENEGAL
150. Tran Pierre Maldonado, LK, Univ. of Puerto Rico, Adults ACTU Site 5401, San Juan,

1. Patricia Manning, Brentwood, CA
2. John Manzon-Santos, Executive Director, Asian & Pacific Islander Wellness Center: Community HIV/AIDS Services, San Francisco, CA
3. Axel Torres Marrero, Director of Public Policy & Legal Services, Hyacinth AIDS Foundation of New Jersey, NJ
4. Thomas G. Martin, Ryan White Planning Council, DC EMA, Washington, DC
5. Betty Martinazzoli, LILA Nazionale, Milan, ITALY
6. Phillip K. Matthews, Executive Director, Test Positive Aware Network, Chicago, IL
7. Tony Maynard, Treatments Officer, Victorian AIDS Council, Melbourne, AUSTRALIA
8. Bob McCormick, Director HIV Dept., Lowell Community Health Center, Lowell, MA & ACTG Community Advisory Board, Harvard/Boston Medical Center AIDS Clinical Trials Unit, Boston, MA
9. Antonio Medina, Letra S Salud, Sexualidad, Sida, MEXICO
10. David Melendez, Humanist Movement
11. Fabio Mesquita, Executive Director, RELARD/La Red Latino Americana de Reducion de Danos (Latin American Harm Reduction Network) Buenos Aires, ARGENTINA
12. Mark Milano, ACT UP New York, New York, NY*
13. Steve Miller, M.D., Infectious Diseases Physician, Johannesburg, South Africa
14. Virgil Rang Moler, Univ. of Puerto Rico, Adults ACTU Site 5401, San Juan, PUERTO RICO
15. Eileen Monaghan, member Pediatric CCG, Brockport, NY
16. Michael J. Monaghan, Max's Dad, Father of HIV boy, 10 yrs. old
17. Jacqueline Montero
18. Don Morrison, CEO, AIDS Services of Dallas, TX
19. Bob Munk, RJM Ph.D., NM
20. Augustus Nasmith, Jr., President, Board of Directors, AIDS, Medicine & Miracles, VT
21. Colin Nee, Director, NAM Publications, UNITED KINGDOM
22. Steven Nesselroth, AIDS in Prison Director,The Osborne Association, New York, NY
23. Lisa Newton, Careteam, Myrtle Beach, SC
24. Layne Nichols, R.N., PWA
25. David Nicklin M.D., Medical Director, Penn Family Care, Presbyterian Hospital, Philadelphia, PA
26. Eduardo Noriega, Union Positiva, Inc., Miami, FL
27. Kevin P. Nuttall, Director, Lighthouse Group, Asheville, NC
28. Lawrence G. Olszewski
29. David G. Ostrow, M.D., Ph.D., Director, HBHC AIM Project, Chicago, IL
30. Lawrence Ouellet, Community Outreach Intervention Projects, Chicago, IL
31. Herminio Palaco, M.D., Special Policy Advisor, San Francisco Dept. of Public Health, S.F., CA
32. John Pappas, AIDS Community Network
33. Christopher Park, International Coordinator, Global Network of People Living with HIV/AIDS, Amsterdam, THE NETHERLANDS
34. Carolyn A. Parker, Ph.D., Texas AIDS Network, TX
35. Roscoe E. Parker, WNC Aids Project, NC
36. Jane Peranteau, Executive Director, Pecos Valley HIV/AIDS Resource Center, Roswell, NM
37. Dr. Stu Peller, Holistic Health Center
38. Marjorie Percival, Coastal AIDS Network, Belfast, ME
39. Federico Hernandez-Plasencia,A.S.G., FASE/Fundaction Anti-SIDA Espana (Spanish Fighting AIDS Foundation), Madrid, SPAIN
40. Michael J. Pugh, American Social Health Association, Research Triangle Park, NC
41. Gary Pujol, Executive Director, AIDS Treatment Initiatives, Atlanta, GA
42. Myron Dean Quon, Staff Attorney, Western Regional Office, Lambda Legal Defense and Education Fund, Inc., Los Angeles, CA
43. Virginia Ramirez, Coordinator, Univ. of Puerto Rico Medical School, Adults ACTU-Site 5401, San Juan, PUERTO RICO
44. Claire Rappoport, Chair, CPCRA CAB, San Francisco, CA
45. Xavier Rey-Coquais, Actions Traitements, Paris, FRANCE
46. Iling Roeg, P.R., Univ. of Puerto Rico Medical School, Adults ACTU-Site 5401, San Juan, PUERTO RICO (signature illegible)
47. Leopoldo Robles, LRA, CAB Member, Univ. of Puerto Rico, Adults ACTU-Site 540l, San Juan, PUERTO RICO
48. Kathleen Rose, RN, AIDS Alliance of Martha's Vineyard, Inc., MA
49. James Rosen, Citizen, Nyack, NY
50. Reda Sadki, MAHA/Migrants Contre le Sida, Bagnolet, FRANCE
51. Jeffrey Schouten, ACTG Community Consortium (CCG), STEP/Seattle Tx. Educ. Project, WA
52. David Scondras, Search for a Cure; Boston, MA
53. Kelly Scott, Seattle, WA
54. Walt Senterfitt, Adv.Chair and BD. Member, Being Alive/Los Angeles & Chief HIV Prevention Epidemiologist, LA County Member, California Prevention Planning Working Group, L.A., CA
55. Carey Sharpe, Case Manager, Careteam, Myrtle Beach, SC
56. Matthew Sharp, ACT UP Golden Gate, S.F.,CA
57. Mike Shriver, NAPWA/ National Association of People with AIDS, Washington, DC
58. Stephen Skuce, Treasurer, ACT UP Boston , Boston, MA
59. Shelley Smith, Treasurer, Lifeforce, Vancouver, WA
60. Clint Spencer, Co-Chair, CAB-AACTG-Hawaii, HAWAII
61. Sean Strub, Founder, POZ Magazine, NY
62. Joan Tallada, GTT/Grupo de Trabajo Sobre Tratamientos Del VIH, Barcelona, SPAIN
63. Mark Tangard
64. Heidi Taubenfeld, Wellness Center of South Florida, FL
65. Jeff Taylor, Chair, University of California, San Diego ACTU Community Advisory Board, CA
66. Veriano Terto Jr., Project Dept. Coordinator, Brazilian Interdisciplinary AIDS Association/ABIA, BRAZIL
67. David L Thomas, Chairman, Regional ACTG CAB, Chicago,IL
68. Joe Thomas, AIDS Advocacy Alliance, Hong Kong, CHINA
69. Russ Tilaro, AIDS Coalition of Chatauqua County, Falconer, NY
70. Martha Underwood, Westat, Inc.
71. Ulrich Wuerdemann, Editor, HIV Nachrichten, GERMANY
72. Rick Vance, MHA, Community Prescription Services, NY
73. Marilyn Vargas, Univ. of Puerto Rico, Adults ACTU Site 5401, San Juan, PUERTO RICO
74. Arturo Vazquez, Letra S Salud, Sexualidad, Sida, MEXICO
75. Enid Vazquez, Associate Editor, Positively Aware, Chicago, IL
76. James P. Vokoun, President, The Colt 45's , Houston, TX
77. Susan S. Wellborn, R.N., F.N.P.
78. Daniel Whelan, Graduate School of International Studies, University of Denver Denver CO
79. Jeff W. White, Asheville, NC
80. David P. Wilson, Executive Director, The Charlotte HIV/AIDS Network Inc., NC
81. Hazel Wilson, AIDS Community Network
82. Robert C. White, St. Louis, MO
83. Mrs. Eka Williams, President, Society for Women and AIDS in AFRICA, Dakar, SENEGAL
84. Jerry Williamson
85. Ulrich Wuerdemann, Editor, HIV Nachrichten, GERMANY
86. Manuel Zozaya, Letra S Salud, Sexualidad, Sida, MEXICO
87. Jose Zuniga, Deputy Director, IAPAC/Int'l. Assoc. of Physicians in AIDS Care, Chicago, IL
88. James Zender, Managing Editor,PWA-RAG/Prisoners with AIDS-Rights Advocacy Groups, Inc.

*ACTUP NEW YORK ENDORSED WITH THE PROVISO THAT THE LAST PARAGRAPH OF CONSENSUS STATEMENT READS AS FOLLOWS:

Therefore, we must clearly state for the record that these drugs must be priced no higher than, and preferably less than, other drugs of their respective classes. We urge manufacturers to immediately begin a dialogue with the community about this pricing issue and not presume it can simply announce a price immediately prior to regulatory approval, without consequences, as a fait accompli.